Novo prevents Teva’s Victoza rival launch until 2023

Novo Nordisk has settled a US patent case with Teva, which prevents the Israel-based generics firm marketing a cheaper version of its key type 2 diabetes drug Victoza until 2023. The Danish pharma said it had reached an agreement following a US patent litigation case for its daily injection Victoza (liraglutide), where Teva is licensed to launch a generic version as of 22 December 2023. Novo said Teva could launch it's generic earlier, but not before March of 2023 unless the Victoza patents are no longer in force or there is another generic on the market. Novo could also get a further stay of execution on Victoza if it is granted an extra six months of patent life for conducting trials of the drug in children. The FDA can grant an extra six months of patent life for drugs if the manufacturer conducts extra trials in children. All other terms of the agreement between the two companies are confidential.